P2Y12 Inhibitors in STEMI Patients - One Size Does Not Fit All
- PMID: 37530947
- PMCID: PMC11098026
- DOI: 10.1007/s10557-023-07497-2
P2Y12 Inhibitors in STEMI Patients - One Size Does Not Fit All
Conflict of interest statement
References
-
- Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;39(2):119–77. - PubMed
-
- Collet J-P, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2021;42(14):1289–367. - PubMed
-
- Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082–115. - PubMed
-
- Perl L, Lerman-Shivek H, Rechavia E, et al. Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2014;63(6):513–7. - PubMed
-
- Flierl U, Zauner F, Sieweke J-T, et al. Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction. Thromb Haemost. 2017;26(01):99–104. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources